Personalized Nasal Spray Rx

About Nectar Lifesciences

Nectar Lifesciences operates a dual-strategy business model, combining a legacy, low-margin API manufacturing operation with a high-growth, direct-to-patient clinical services segment. Founded in 1995, the company has achieved significant scale with a $1.81B valuation, driven by its vertically integrated manufacturing capabilities and regulatory approvals from the US FDA and UK MHRA. Its strategic pivot into the US allergy care market represents a bold move to capture higher margins and recurring revenue from a large, underserved patient population, though it creates a unique and complex corporate profile.

Therapeutic Areas